Gaucher disease (GD) is a lysosomal storage disorder for which safe and effective intravenous enzyme replacement therapy (ERT) has been available for more than 25 years. 1 The safety of the several ERTs for GD has also afforded the possibility of home infusions, reported by patients to be less stressful than those received in the hospital setting. 2 ERT is usually a life-long commitment to infusions, and many patients find the every-other-week (EOW) hourly infusions onerous, impacting aspects of their quality of life, including time taken off school/work. Over the past 2 decades, we became aware of several anecdotal reports from patients who while responsible for their infusions at home, decreased the infusion duration from the standard 60 min to as little as 2-5 min without apparent untoward effect.
shows the timeline of the study design. The volume for each infusion in the study was set at 100 mL, controlled with an infusion pump (hospital) and by gravity (home). This study was a prospective study. The protocol guaranteed the safety of the patient by measuring blood pressure, heart rate and temperature at four time points during the hospital clinic setting (ie, 10 min prior, at the start, at the end of infusion and 1 h after the start of the infusion) and at the home setting (ie, blood pressure was measured before and after the infusion).
Inclusion criteria for the study were: age ≥ 18 years, nonsplenectomized, ≥ 3 months exposure to velaglucerase alfa at a stable dose with no infusion-related or drug-related adverse events (AEs) and no clinically significant comorbidities. Safety was the primary end-point as determined by AEs during or directly after infusions as monitored by an experienced nurse. Efficacy parameters included hemoglobin concentration and platelet counts, spleen and liver volume estimation by ultrasound and determination of the biomarker glucosylsphingosine (lyso-Gb1) (Centogene, Rostock, Germany). 5 Drug concentration was assessed in plasma samples taken at time 0-90 min posttransfusion at study baseline, that is, 60-min transfusion, and at end-of-study (EOS), that is, 10-min transfusion. Nonvalidated questionnaire of 7 visual analog scales in Hebrew was used to assess disease impact.
These were continua of 0-10 points, worst case to best case scenarios regarding: (1) dependence, (2) constant fatigue, (3) unremitting bone pain, (4) depression related to GD, (5) dissatisfaction with treatment, (6) family severely impacted by GD, and (7) pessimistic about future.
Local institutional review board approval was granted for the study, and all participating patients provided written informed consent before commencing study procedures.
Descriptive statistics were employed. Baseline and 9 months hematologic parameters, spleen, and liver volume estimation and lysoGb1 levels were compared using the paired t test for normally distributed data. Statistical analysis was performed with SPSS statistical package (version 22 for Windows). A P value < .05 was considered significant.
Fifteen patients, mean age 32 (range 22-44) years, genotype N370S homozygous (N = 7) or heterozygous, were recruited (Supporting Information Table S1 ). No patient had AEs while receiving velaglucerase alfa infusions for a mean of 9.6 (range: 2.5-17) years. All patients were maintained on prestudy dosages (15-60 units/kg body weight)/infusion EOW.
There were no severe AEs associated with the 10-min infusions, in the clinic or at home; the only mild AE was a single female patient who experienced discomfort (feeling cold) in the infused arm during two 10-min infusions. This patient subsequently became pregnant and was withdrawn from the trial. A second patient withdrew for personal reasons.
All the patients maintained stability in the key disease features including the hematological parameters, organ volumes, and lyso-Gb1 levels (Supporting Information Table S1 ; P > .1). The drug concentration/time curves differed in peak levels (higher for 10-min infusion)
and width (longer for the 60-min infusion) (Supporting Information 
